Lantheus Holdings to Shine at the Upcoming Conference
Lantheus Holdings, Inc. (NASDAQ: LNTH), a prominent name in the radiopharmaceutical sector, recently made waves by announcing that the CEO, Brian Markison, will take the stage at the Morgan Stanley 23rd Annual Global Healthcare Conference. The presentation is scheduled for 7:00 a.m. ET on an upcoming Tuesday, where Lantheus aims to highlight its mission to help healthcare professionals Find, Fight, and Follow diseases effectively.
Strategic Presentation Approach
During this pivotal event, the leadership team from Lantheus will delve into the company's cutting-edge advancements in the field of radiopharmaceuticals. As a leader in this niche, Lantheus emphasizes research and development, striving to improve diagnostic and therapeutic modalities that foster superior patient care and outcomes. This is an excellent opportunity for investors and healthcare stakeholders to gain insight into the strategic direction of Lantheus Holdings.
Webcast Access for Interested Parties
For those eager to engage with the presentation, Lantheus has made it convenient to access via a live webcast through the Investors section of its corporate website. After the live event, a replay will be available online for a minimum of 30 days, allowing interested parties to catch up on invaluable insights at their convenience.
An Overview of Lantheus
Lantheus has carved out an impressive reputation as a go-to source for innovative radiopharmaceutical solutions over the course of nearly 70 years. Headquartered in Massachusetts and operating internationally, the company has expanded to include offices in New Jersey, Canada, Germany, Sweden, and Switzerland. By focusing on life-changing science, Lantheus dedicates itself to helping clinicians enhance patient outcomes through its state-of-the-art technologies.
Company Contact Information
For investor inquiries or communications related to the company's operations, Lantheus encourages interested parties to reach out directly to Mark Kinarney, Vice President of Investor Relations at 978-671-8842, or email ir@lantheus.com. For media inquiries, Melissa Downs, Executive Director of External Communications, can be contacted at 646-975-2533 or via email at media@lantheus.com.
Frequently Asked Questions
What is the purpose of Lantheus's presentation at the conference?
The presentation aims to highlight Lantheus's groundbreaking advancements in radiopharmaceuticals and its commitment to enhancing healthcare outcomes.
How can I access the live webcast?
The live webcast will be available on the Investors section of the Lantheus website, with a replay accessible for at least 30 days afterwards.
What does Lantheus focus on in its operations?
Lantheus specializes in radiopharmaceuticals, developing innovative solutions to aid clinicians in diagnosing and treating diseases effectively.
How long has Lantheus been in operation?
Lantheus has been providing radiopharmaceutical solutions for nearly 70 years, establishing a legacy of excellence in healthcare.
Who can I contact for more information about Lantheus?
Contacts for inquiries include Mark Kinarney for investors and Melissa Downs for media related questions.
